human array Search Results


98
R&D Systems proteome profilertm human xl cytokine array kit
Proteome Profilertm Human Xl Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profilertm human xl cytokine array kit/product/R&D Systems
Average 98 stars, based on 1 article reviews
proteome profilertm human xl cytokine array kit - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

96
R&D Systems proteome profiler human phospho mapk array kit
Proteome Profiler Human Phospho Mapk Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler human phospho mapk array kit/product/R&D Systems
Average 96 stars, based on 1 article reviews
proteome profiler human phospho mapk array kit - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

95
R&D Systems proteome profiler human protease array kit
Proteome Profiler Human Protease Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler human protease array kit/product/R&D Systems
Average 95 stars, based on 1 article reviews
proteome profiler human protease array kit - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

95
R&D Systems human xl oncology array kit
Human Xl Oncology Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human xl oncology array kit/product/R&D Systems
Average 95 stars, based on 1 article reviews
human xl oncology array kit - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

98
R&D Systems human cytokine antibody array panel a
Differentiation assay of Pl/Mb-MSCs in comparison to BM-MSCs and cytokines expression. (a) Representative differentiation of Pl/Mb-MSCs passage 4 is shown. Cells were kept in induction medium (differentiation) or control standard medium (control). (a–d) Osteogenic and adipocyte differentiation and control for BM-MSCs. (f–h) Osteogenic and adipocyte differentiation and control for Mb-MSCs. (b) <t>Cytokine</t> expressions of Mb-MSCs and BM-MSCs using the proteome profiler. (c) Quantification of cytokine optical density. Measurements were obtained with image J software (NIH).
Human Cytokine Antibody Array Panel A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cytokine antibody array panel a/product/R&D Systems
Average 98 stars, based on 1 article reviews
human cytokine antibody array panel a - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

92
R&D Systems proteome profiler human ubiquitin array kit
Differentiation assay of Pl/Mb-MSCs in comparison to BM-MSCs and cytokines expression. (a) Representative differentiation of Pl/Mb-MSCs passage 4 is shown. Cells were kept in induction medium (differentiation) or control standard medium (control). (a–d) Osteogenic and adipocyte differentiation and control for BM-MSCs. (f–h) Osteogenic and adipocyte differentiation and control for Mb-MSCs. (b) <t>Cytokine</t> expressions of Mb-MSCs and BM-MSCs using the proteome profiler. (c) Quantification of cytokine optical density. Measurements were obtained with image J software (NIH).
Proteome Profiler Human Ubiquitin Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler human ubiquitin array kit/product/R&D Systems
Average 92 stars, based on 1 article reviews
proteome profiler human ubiquitin array kit - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

96
R&D Systems proteome profiler apoptotic array kit
A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early <t>apoptotic</t> (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
Proteome Profiler Apoptotic Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler apoptotic array kit/product/R&D Systems
Average 96 stars, based on 1 article reviews
proteome profiler apoptotic array kit - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

96
R&D Systems proteome profiler human angiogenesis array
A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early <t>apoptotic</t> (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
Proteome Profiler Human Angiogenesis Array, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler human angiogenesis array/product/R&D Systems
Average 96 stars, based on 1 article reviews
proteome profiler human angiogenesis array - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

96
R&D Systems proteome profiler human xl cytokine array kit
A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early <t>apoptotic</t> (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
Proteome Profiler Human Xl Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler human xl cytokine array kit/product/R&D Systems
Average 96 stars, based on 1 article reviews
proteome profiler human xl cytokine array kit - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

98
R&D Systems human phospho kinase antibody array kit
A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early <t>apoptotic</t> (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
Human Phospho Kinase Antibody Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human phospho kinase antibody array kit/product/R&D Systems
Average 98 stars, based on 1 article reviews
human phospho kinase antibody array kit - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

95
R&D Systems crt mg
A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early <t>apoptotic</t> (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
Crt Mg, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crt mg/product/R&D Systems
Average 95 stars, based on 1 article reviews
crt mg - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

97
R&D Systems proteome profiler antibody based angiogenesis array
A, Bazedoxifene inhibits tube formation. HUVECs were seeded on Matrigel-coated wells with VEGF (10 ng/ml) in the absence or in the presence of Bazedoxifene and incubated for 24 hours to form a capillary network. The total number of branched tubes was then counted and representative image of capillary network formation was taken. B, Bazedoxifene downregulates several angiogenic factors in vitro . The <t>proteome</t> profiler antibody <t>angiogenesis</t> array was performed. The relative level of selected angiogenesis-related proteins was determined in parallel between untreated (left) and treated (right) HUVEC cells. C, Bazedoxifene inhibits endothelial cellular invasion. HUVECs (1 × 10 6 cells/ml) were added to transwell chamber coated with Matrigel and treated with VEGF (20 ng/ml) in the absence or in presence of Bazedoxifene. After 24 hours, the number of invaded cells was counted, and results are expressed as percentage of invasion (basal invasion with no treatment). D, Bazedoxifene blocks rhabdomyosarcoma cells invasion. Parental RH30 and RH28 cells were starved in 0% FBS medium for 24 hours. After that, cells were seeded (5 × 10 4 cells/well) to the top chamber, and 10% FBS was added into the lower chamber. Cells were treated with Bazedoxifene for 24 hours, and then invasion cells were detected in the bottom chamber using a Cultrex BME Cell Invasion Assay. Statistical analysis of three independent experiments was shown as means, *, P < 0.05.
Proteome Profiler Antibody Based Angiogenesis Array, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteome profiler antibody based angiogenesis array/product/R&D Systems
Average 97 stars, based on 1 article reviews
proteome profiler antibody based angiogenesis array - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier

Image Search Results


Differentiation assay of Pl/Mb-MSCs in comparison to BM-MSCs and cytokines expression. (a) Representative differentiation of Pl/Mb-MSCs passage 4 is shown. Cells were kept in induction medium (differentiation) or control standard medium (control). (a–d) Osteogenic and adipocyte differentiation and control for BM-MSCs. (f–h) Osteogenic and adipocyte differentiation and control for Mb-MSCs. (b) Cytokine expressions of Mb-MSCs and BM-MSCs using the proteome profiler. (c) Quantification of cytokine optical density. Measurements were obtained with image J software (NIH).

Journal: Stem Cells International

Article Title: Comprehensive Characterization of Mesenchymal Stem Cells from Human Placenta and Fetal Membrane and Their Response to Osteoactivin Stimulation

doi: 10.1155/2012/658356

Figure Lengend Snippet: Differentiation assay of Pl/Mb-MSCs in comparison to BM-MSCs and cytokines expression. (a) Representative differentiation of Pl/Mb-MSCs passage 4 is shown. Cells were kept in induction medium (differentiation) or control standard medium (control). (a–d) Osteogenic and adipocyte differentiation and control for BM-MSCs. (f–h) Osteogenic and adipocyte differentiation and control for Mb-MSCs. (b) Cytokine expressions of Mb-MSCs and BM-MSCs using the proteome profiler. (c) Quantification of cytokine optical density. Measurements were obtained with image J software (NIH).

Article Snippet: 200 μ g of protein was loaded on R&D system Human Cytokine Antibody Array panel A (R&D system, number ARY005) according to manufacturer's instructions.

Techniques: Differentiation Assay, Comparison, Expressing, Control, Software

A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early apoptotic (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.

Journal: American Journal of Cancer Research

Article Title: Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway

doi: 10.62347/JTNQ4812

Figure Lengend Snippet: A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early apoptotic (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.

Article Snippet: Protein array analysis Human apoptosis array analysis was performed using a proteome profiler apoptotic array kit (ARY009; R & D system.

Techniques: Concentration Assay, Flow Cytometry, Staining, Control

A. The Pp53 and P21 signalling pathways are strongly activated by TDEF treatment. The human apoptosis proteome profiler array used a protein extract (400 µg). The intensities of each array spot were visualized and further quantified using an image. B. The graph shows the relative fold change of proteins with significant differences upon TDEF treatment, setting 1 for control (no treatment of TDEF). Protein levels with higher than ± 2 folds are considered candidates for TDEF-induced cell death.

Journal: American Journal of Cancer Research

Article Title: Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway

doi: 10.62347/JTNQ4812

Figure Lengend Snippet: A. The Pp53 and P21 signalling pathways are strongly activated by TDEF treatment. The human apoptosis proteome profiler array used a protein extract (400 µg). The intensities of each array spot were visualized and further quantified using an image. B. The graph shows the relative fold change of proteins with significant differences upon TDEF treatment, setting 1 for control (no treatment of TDEF). Protein levels with higher than ± 2 folds are considered candidates for TDEF-induced cell death.

Article Snippet: Protein array analysis Human apoptosis array analysis was performed using a proteome profiler apoptotic array kit (ARY009; R & D system.

Techniques: Control

A, Bazedoxifene inhibits tube formation. HUVECs were seeded on Matrigel-coated wells with VEGF (10 ng/ml) in the absence or in the presence of Bazedoxifene and incubated for 24 hours to form a capillary network. The total number of branched tubes was then counted and representative image of capillary network formation was taken. B, Bazedoxifene downregulates several angiogenic factors in vitro . The proteome profiler antibody angiogenesis array was performed. The relative level of selected angiogenesis-related proteins was determined in parallel between untreated (left) and treated (right) HUVEC cells. C, Bazedoxifene inhibits endothelial cellular invasion. HUVECs (1 × 10 6 cells/ml) were added to transwell chamber coated with Matrigel and treated with VEGF (20 ng/ml) in the absence or in presence of Bazedoxifene. After 24 hours, the number of invaded cells was counted, and results are expressed as percentage of invasion (basal invasion with no treatment). D, Bazedoxifene blocks rhabdomyosarcoma cells invasion. Parental RH30 and RH28 cells were starved in 0% FBS medium for 24 hours. After that, cells were seeded (5 × 10 4 cells/well) to the top chamber, and 10% FBS was added into the lower chamber. Cells were treated with Bazedoxifene for 24 hours, and then invasion cells were detected in the bottom chamber using a Cultrex BME Cell Invasion Assay. Statistical analysis of three independent experiments was shown as means, *, P < 0.05.

Journal: PLoS ONE

Article Title: Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

doi: 10.1371/journal.pone.0180297

Figure Lengend Snippet: A, Bazedoxifene inhibits tube formation. HUVECs were seeded on Matrigel-coated wells with VEGF (10 ng/ml) in the absence or in the presence of Bazedoxifene and incubated for 24 hours to form a capillary network. The total number of branched tubes was then counted and representative image of capillary network formation was taken. B, Bazedoxifene downregulates several angiogenic factors in vitro . The proteome profiler antibody angiogenesis array was performed. The relative level of selected angiogenesis-related proteins was determined in parallel between untreated (left) and treated (right) HUVEC cells. C, Bazedoxifene inhibits endothelial cellular invasion. HUVECs (1 × 10 6 cells/ml) were added to transwell chamber coated with Matrigel and treated with VEGF (20 ng/ml) in the absence or in presence of Bazedoxifene. After 24 hours, the number of invaded cells was counted, and results are expressed as percentage of invasion (basal invasion with no treatment). D, Bazedoxifene blocks rhabdomyosarcoma cells invasion. Parental RH30 and RH28 cells were starved in 0% FBS medium for 24 hours. After that, cells were seeded (5 × 10 4 cells/well) to the top chamber, and 10% FBS was added into the lower chamber. Cells were treated with Bazedoxifene for 24 hours, and then invasion cells were detected in the bottom chamber using a Cultrex BME Cell Invasion Assay. Statistical analysis of three independent experiments was shown as means, *, P < 0.05.

Article Snippet: Proteome profiler antibody based Angiogenesis array (R & D systems; Cat. No. ARY007) was used according to manufacturer’s instructions to detect the relative levels of expression of angiogenesis related proteins in control and Bazedoxifene treated cells.

Techniques: Incubation, In Vitro, Invasion Assay